SCHEMBL20488303

SCHEMBL20488303

CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccc(C(=O)O)cc43)c3ccccc3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.49
MELK Q14680 9/20 0.48
CHEK1 O14757 3/20 0.48
PRKAB2 O43741 3/20 0.48
NUAK1 O60285 3/20 0.48
MAPK1 P28482 3/20 0.48
PRKAG1 P54619 3/20 0.48
PRKAA2 P54646 3/20 0.48
PRKAA1 Q13131 3/20 0.48
CAMKK2 Q96RR4 3/20 0.48
PRKAG3 Q9UGI9 3/20 0.48
PRKAG2 Q9UGJ0 3/20 0.48
PRKAB1 Q9Y478 3/20 0.48
PDGFRB P09619 7/20 0.44
FGFR1 P11362 7/20 0.44
KDR P35968 7/20 0.44
PDGFRA P16234 2/20 0.44
FLT1 P17948 2/20 0.44
FGFR2 P21802 2/20 0.44
FGFR4 P22455 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20488309 1.00 AAK1 (0.49) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20487139 0.94 AAK1 (0.45) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20488348 0.94 MELK (0.49) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20487144 0.94 AAK1 (0.45) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20488349 0.94 MELK (0.49) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20488222 0.94 AAK1 (0.45) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20487476 0.94 AAK1 (0.45) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20488220 0.94 AAK1 (0.45) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL20487451 0.94 AAK1 (0.45) AAK1MELKCHEK1PRKAB2NUAK1
SCHEMBL851519 0.94 AAK1 (0.50) AAK1MELKCHEK1PRKAB2NUAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-05-01 US disclosed
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US disclosed
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US disclosed
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-20 US disclosed
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-20 US disclosed
WO-2018160967-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317107-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 AAK1 65/4885MELK 1/4885CHEK1 252/4885
US-10981896-B2 Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase MELK, HIPK1, HIPK3 AAK1 88/4885MELK 1/4885CHEK1 310/4885
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 AAK1 65/4885MELK 1/4885CHEK1 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.